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Abstract 
Objective: Although aspirin has been associated with a reduction of the risk of cancer when used 
as a nonsteroidal anti-inflammatory drug, its use to reduce the risk of ovarian cancer is contro-
versial. Ovarian cancer cells usually express high levels of cyclooxygenase-1 (COX)-1. Because 
aspirin is a rather selective inhibitor of COX-1, the ability of aspirin to reduce the risk of ovarian 
cancer may be dependent on the level of COX-1 expression in those cells. Furthermore, epi-
dermal growth factor receptor (EGFR) is frequently overexpressed in the malignant phenotype of 
ovarian cancer leading to increased cell proliferation and survival. Here we investigated if aspirin 
attenuates EGFR-activated ovarian cancer cell growth in a COX-1 dependent manner. 
Methods: Cell viability assays and Western blot analyses were used to determine the effect of 
aspirin on EGF-stimulated cell proliferation. Gene silencing and gene expression techniques were 
employed to knockdown or to express COX-1, respectively.  
Results: Aspirin inhibited cell viability induced by EGF in a dose dependent manner in COX-1 
positive ovarian cancer cells. On the other hand, aspirin had no effect on cell viability in COX-1 
negative ovarian cancer cells. In particular, aspirin decreased phosphorylated Akt and Erk activated 
by EGF. COX-1 silencing in COX-1 positive cells attenuated the inhibitory effect of aspirin on 
EGF-stimulated cell viability. Furthermore, we developed a COX-1 expressing cell line (SKCOX-1) 
by stably transfecting COX-1 expression vector into COX-1 negative SKOV-3 cells. SKCOX-1 
cells were more responsive to aspirin when compared to cells transfected with empty vector, and 
decreased EGF-activated Akt and Erk as well as cell viability. 
Conclusions: Taken together, aspirin inhibits viability of ovarian cancer cells by blocking phos-
phorylation of Akt and Erk activated by EGF. Thus it may potentiate the therapeutic efficacy of 
drugs used to treat COX-1 positive ovarian cancer subsets. 
Key words: ovarian cancer, aspirin, COX-1, EGF, Erk, Akt, cell viability. 
Introduction 
Ovarian cancer is the deadliest gynecologic ma-
lignancy and is the fifth cause of cancer death in 
women in the United States [1, 2]. Ovarian cancer 
typically is asymptomatic until tumors have spread 
far beyond the ovaries. Unfortunately to date, there 








Thus, it is not surprising that the 5-year survival rate 
for ovarian cancer has not changed much over the 
past several decades despite the introduction of in-
tensive surgical treatments and advances in the use of 
novel therapeutic agents [2]. Therefore new diagnostic 
biomarkers and therapeutic options are needed to 
reduce the morbidity and mortality observed with 
advanced stage ovarian cancer. 
Chronic inflammation has been proposed as a 
risk factor for ovarian cancer [3, 4]. Aspirin (acetyl-
salicylate) is one of the most commonly used non-
steroidal anti-inflammatory drugs in the United States 
[5], and its use has increased significantly over the last 
5 years [6]. Although the accumulated evidence shows 
that aspirin use is associated with a reduced risk of 
prostate [7, 8], breast [9], colorectal [9, 10] and endo-
metrial cancer [11], the relationship between aspirin 
and ovarian cancer risk remains controversial. Some 
investigators have found no association [9, 12-14] 
while others reported an inverse association between 
the use of aspirin and ovarian cancer [15-17]. Our 
group and others have demonstrated that most epi-
thelial ovarian cancer cells express high levels of cy-
clooxygenase-1 (COX)-1 rather than COX-2 [18, 19]. 
Therefore, COX-1 could be a potential therapeutic 
target for the prevention and/or treatment of ovarian 
cancer [20, 21].  
Aspirin is a relatively selective COX-1 inhibitor 
[5] and has been shown to suppress cell growth in 
COX-1 expressing ovarian cancer cells [18-20, 22]. Our 
group has shown in a previous study that aspirin po-
tentiates the effectiveness of histone deacetylase in-
hibitors by upregulating cell cycle arrest protein p21 
in COX-1 positive ovarian cancer cells, but not in 
COX-1 negative cells [23]. These findings support the 
concept that the effectiveness of aspirin may be linked 
to the degree of COX-1 expression in ovarian cancer 
cells.  
Ovarian cancer has been associated with many 
genetic and epigenetic changes that occur during the 
progression from a benign to a malignant stage. One 
of the alterations in high-grade malignant ovarian 
cancer is overexpression of the epidermal growth 
factor receptor (EGFR) [24, 25]. EGFR inhibitors are 
potentially useful therapeutic agents in patients with 
advanced or recurrent ovarian cancers [26-28]. How-
ever, clinical trials have been disappointing. Here we 
asked if modulating COX-1 could be a method for 
improving upon current EGFR targeted therapy. To 
our knowledge, little is known about the effects of 
aspirin on EGFR signaling in COX-1 abundant ovar-
ian cancer cells. In the present study, we demon-
strated that aspirin attenuates EGFR-activated ovari-
an cancer cell viability in a COX-1 dependent manner. 
These results have important implications for defin-
ing COX-1 positive ovarian cancer subsets and con-
sidering aspirin for enhancing the therapeutic efficacy 
of EGFR inhibitors.  
Materials and Methods 
Reagents 
Aspirin (acetylsalicylate) was purchased from 
Sigma (St. Louis, MO). Recombinant human EGF was 
obtained from R&D Systems (Minneapolis, MN). An-
tibodies for COX-1, COX-2 and β-actin were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA) and 
antibodies for Erk, p38, SAPK/JNK, Akt, EGFR and 
their phosphorylated forms were obtained from Cell 
Signaling Technology (Danvers, MA). Chemilumi-
nescent detection kits came from GE Healthcare. All 
liquid culture media were acquired from Invitrogen 
Life Technologies (Grand Island, NY). Pre-designed 
siRNAs for nontargeting controls and COX-1 experi-
ments were purchased from Dharmacon (Lafayette, 
CO). 
Cell culture 
The human ovarian cancer cell lines (OVCAR-3, 
SKOV-3, TOV-21G and CaOV-3) and human THP-1 
monocyte line were purchased from the American 
Type Culture Collection and the A2780 human ovar-
ian cancer cell line was provided by Dr. Andrew 
Godwin (University of Kansas, Kansas City, KS). Cells 
(approximately 5 X 104 cells/ml) were cultured at 
37°C in a water-saturated atmosphere of 95% air and 
5% CO2 with 10% FBS containing RPMI medium with 
penicillin/streptomycin. After an overnight culture to 
allow cellular attachment to the plates, the medium 
was removed and fresh medium without FBS was 
added to remove the effects of serum, per se. Where 
indicated, cells were treated with aspirin, EGF, or a 
combination of both, as detailed under Results. 
Cell viability assays 
Cell viability assays were performed using the 
cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) to a colored 
product. After a 48 hour incubation in a 24-well plate, 
each well was washed twice with phenol red-free 
media and then MTT solution (1 mg/ml of phenol 
red-free media: PBS = 4:1) was added. The plates were 
incubated for 3 hours with protection from light. The 
MTT solution was removed and 500 µl of isopropanol 
was added. The plates were placed on a shaker for 10 
minutes at room temperature to thoroughly dissolve 
the MTT color product. Optical density was measured 
at 595 nm using a microplate reader (Bio-Rad, Hercu-
les, CA).  





Whole-cell lysates were prepared, fractionated 
on SDS-polyacrylamide gels and transferred to nitro-
cellulose membranes according to established proce-
dures. Blocking of nonspecific proteins was per-
formed by incubation of the membranes with 5% 
nonfat dry milk in Tris-buffered saline Tween-20 
(TBST containing 10 mM Tris, 150 mM phosphate 
buffered saline, 0.05% Tween 20, pH 8.0) for 2 hours at 
room temperature. The following primary antibodies 
were used: COX-1 and COX-2 (Santa Cruz Biotech-
nology, Santa Cruz, CA) and EGFR, Erk, p38, 
SAPK/JNK, Akt and their phosphorylated forms (Cell 
Signaling Technology, Beverly, MA). After an over-
night incubation at 4°C, the membranes were washed 
3 times with TBST for 10 minutes, followed by incu-
bation for 1 hour with horseradish peroxidase conju-
gated secondary antibody according to each primary 
antibody. The membranes were then rinsed 3 times 
with TBST for 10 minutes, and the bands were visu-
alized by enhanced chemiluminescence detection kits 
from GE Healthcare (Piscataway, NJ). After mem-
brane stripping for 10 min with methanol containing 
3% H2O2, β-actin (Santa Cruz Biotechnology, Santa 
Cruz, CA) was detected in order to serve as an inter-
nal loading control of cell lysates.  
Gene silencing with small interfering RNA 
transfection 
Gene expression level of COX-1 was selectively 
knocked down by using pre-designed siRNAs 
(ON-TARGET plus Duplex PTGS1) obtained from 
Dharmacon (Lafayette, CO). A non-targeting siRNA 
(NT1) was used as a negative control. OVCAR-3 cells 
were transiently transfected with 10 nmol/L siRNA 
(final concentration of maximum knock-down) for 72 
hours using the transfection reagent. After adding 
new media, cells were treated as described in Results 
and the cell proliferation assay was performed 48 
hours after addition of EGF. Western blots were per-
formed to validate the silencing of protein expression. 
Generation of a COX-1 stable ovarian cancer 
cell line 
COX-1 null SKOV-3 cells were stably transfected 
with a pcDNA based COX-1 expression vector which 
was a kind gift from Dr. S.K. Dey (Cincinnati Chil-
dren's Hospital Medical Center, Cincinnati, OH) fol-
lowed by G418 (Sigma) selection. Cell transfection 
was performed following the protocol of Lipofec-
tamine 2000 (Invitrogen). The empty vector trans-
fected cells were used as controls (SKpcDNA cells). 
After 12 days, resistant colonies were selected to con-
firm COX-1 expression (SKCOX-1 cells). 
Statistics 
Each experiment was repeated at least in tripli-
cate. Data were analyzed by the paired Student’s t-test 
and one-way analysis of variance (ANOVA) as ap-
propriate. If statistical significance (p ≤ 0.05) was de-
termined by ANOVA, the data were further analyzed 
by Tukey’s pairwise comparisons to detect specific 
differences between treatments. 
Results 
Aspirin inhibits COX-1 positive ovarian cancer 
cell viability but not in COX-1 negative cells 
We employed the ovarian cancer cell lines 
OVCAR-3, SKOV-3, A2780 and TOV-21G to examine 
effects of aspirin on cell proliferation. We selected 1 
mmol/L of aspirin as a maximum concentration for 
treatment, based on the mean maximum concentra-
tion 10.4-12.2 mg/dL at 180 minutes after dosing 
humans with 1,950 mg of aspirin per mean weight of 
73.3 kg [29]. Furthermore, we found that a higher 
concentration than 1 mmol/L of aspirin was not 
suitable for cell incubations because of a resultant pH 
change in the culture media. Results indicated that 
aspirin inhibited cell viability in OVCAR-3 cells in a 
dose-dependent manner but not in SKOV-3, A2780 
and TOV-21G cells (figure 1A). Since aspirin is a rela-
tively selective COX-1 inhibitor compared to COX-2 
[5], the expression status of COX-1 and COX-2 pro-
teins were compared in all ovarian cancer cells tested. 
Only OVCAR-3 cells expressed COX-1 whereas other 
cancer cells did not (figure 1B), as previously pub-
lished [23]. COX-2 was not expressed in any of the 
ovarian cancer cells tested (figure 1B).  
Aspirin inhibits EGFR-activated cell viability in 
COX-1 positive ovarian cancer cells 
High-grade malignant ovarian cancers fre-
quently overexpress EGFR, which contributes to cel-
lular proliferation, survival and motility [24, 25, 30]. 
First, we checked a dose-dependent effect of EGF on 
cell viability in OVCAR-3 cells. EGF increased maxi-
mally cell viability at 5 ng/ml in OVCAR-3 cells (fig-
ure 2A). So we used 10 ng of EGF/ml of medium as a 
final concentration and examined if aspirin affected 
EGFR-activated ovarian cancer cell viability. EGF in-
creased cell viability in OVCAR-3 cells and aspirin 
blocked the EGFR-activated cell viability in a 
dose-dependent manner (figure 2B). We also investi-
gated the effect of aspirin on the PI3K/Akt pathway 
which is also known as a primary downstream sig-
naling pathway linked to EGFR activation. EGF in-
duced Akt phosphorylation and aspirin inhibited 
EGFR-activated Akt in OVCAR-3 cells (figure 2C). 
Furthermore, EGF activated Erk within 5-15 minutes 




and pre-addition of aspirin inhibited the 
EGFR-activated Erk in OVCAR-3 cells. However, EGF 
did not activate p38 MAPK or SAPK/JNK (figure 2D). 
EGFR activation, upstream of Akt and Erk signaling, 
also was inhibited by aspirin (figure 2C). 
Silencing COX-1 abrogates inhibitory effect of 
aspirin on cell viability in OVCAR-3 cells 
We used COX-1 siRNA to knockdown COX-1 to 
help determine whether COX-1 activity, per se, con-
tributed to the inhibitory effect of aspirin on cell via-
bility. We first confirmed COX-1 knockdown by 
COX-1 siRNA (figure 3A). We found that COX-1 
knockdown blocked the inhibitory effect of aspirin on 
both basal and EGF-induced cell viability in 
OVCAR-3 cells when compared to control siRNA 
(figure 3B).  
COX-1 expressing cells contribute to cell via-
bility when compared to COX-1 null cells  
We made COX-1 expressing cells by stably 
transfecting COX-1 expression vector into the COX-1 
null parental SKOV-3 cell line to produce SKCOX-1 
(COX-1 vector) cells. SkpcDNA (empty vector) trans-
fected cells served as a control. We confirmed COX-1 
expression in SKCOX-1 cells (figure 4A). We then 
compared cell viability in SkpcDNA versus SKCOX-1 
cells. Cell viability was significantly greater in COX-1 
expressing SKCOX-1 cells compared to COX-1 null 
SKpcDNA cells (figure 4B) when examined after 48 
and 72 hours of incubation (figure 4B).  
Overexpression of COX-1 increases cell via-
bility in response to EGF and aspirin blocks the 
response 
We examined whether COX-1 contributes to EGF 
responsiveness by comparing the effects of EGF in 
SKpcDNA and SKCOX-1 cells. EGF significantly in-
creased cell viability in SKCOX-1 cells but not in 
SKpcDNA cells (figure 5A and 5B). In addition, aspi-
rin inhibited EGFR-activated cell viability only in 
SKCOX-1 cells (figure 5B). Furthermore, EGF acti-
vated EGFR, Erk and Akt in both SKpcDNA and 
SKCOX-1 cells, but aspirin inhibited EGFR, Erk and 
Akt activation in SKCOX-1 cells but not in SKpcDNA 
cells (figure 5C and 5D).  
 
Fig 1. Aspirin differentially regulates cell viability in COX-1 positive versus negative ovarian cancer cells. (A) Effects of aspirin on cellular 
proliferation in ovarian cancer cell lines OVCAR-3, SKOV-3, A2780 and TOV-21G. Cells were treated for 48 hours with aspirin (0.25, 0.5 and 1 mmol/L) 
in a dose-dependent manner. The cell viability assay was performed by using MTT, and values were normalized to untreated controls. Experiments were 
performed in triplicate and all data are shown as mean ± SE. # Indicates a significant decrease (p≤0.05) using ANOVA and Tukey’s pairwise analyses. (B) 
COX-1 and COX-2 protein expressions were evaluated in ovarian cancer cell lines by western blot. β-actin was used as a loading control. As a positive 
control of COX-2, SW480 cells were used at 30 minute TNF (10 ng/ml) post-treatment.  





Fig 2. ASA decreases EGFR-activated cell viability by blocking phosphorylation of Erk and Akt. (A) A dose-dependant effect of EGF on cell 
viability in COX-1 positive OVCAR-3 cells. Cells were treated for 48 hours with EGF (0-40 ng/ml). *, ** Indicates a significant increase (p≤0.05) using 
ANOVA and Tukey’s pairwise analyses. (B) Effects of aspirin on EGFR-activated cell viability in COX-1 positive OVCAR-3 cells. Cells were treated for 48 
hours with aspirin (0.25, 0.5 and 1 mmol/L) in the absence or presence of EGF (10 ng/ml). The cell proliferation assay was performed using MTT, and values 
were normalized to untreated controls. Experiments were performed in triplicate and all data are shown as means ± SE. *, # Indicate a significant increase 
or decrease (p≤0.05), respectively, by Student’s-t test. The inhibitory effect of aspirin on EGFR, Akt (C) Erk (D) activation in OVCAR-3 cells by Western 
blot. Cells were pretreated with aspirin (1 mmol/L) for 24 hours followed by EGF (10 ng/ml) treatment for 0-120 minutes as shown. pEGFR (tyr1068), pAkt, 
pErk, pp38 and pSAPK/JNK indicate phosphorylated EGFR, Akt, Erk, p38, and SAPK/JNK, respectively. β-Actin was used as a loading control. As positive 
controls for phosphorylated p38 and SAPK/JNK, SW480 cells were used at 30 minute TNF (10 ng/ml) post-treatment. 
 
 
Fig 3. Silencing COX-1 with a small interfering RNA blocks inhibitory effect of aspirin on cell viability in OVCAR-3 cells. (A) Confirma-
tion of COX-1 knockdown in OVCAR-3 cells by using COX-1 siRNA. Whole cell lysates were prepared and a western blot was carried out using COX-1 
specific antibody. β-Actin was used as a loading control. (B) Effects of COX-1 siRNA on the inhibitory effect of aspirin on basal and EGF-stimulated cell 
viability in OVCAR-3 cells. Cells were transiently transfected with Control or COX-1 siRNAs (final concentration 10 nmol/L) for 48 hours followed by 
treatment for 48 hours with EGF (10 ng/mL). A cell viability assay was performed using MTT and values were normalized to untreated controls. Ex-
periments were performed in triplicate and all data are shown as means ± SE. *, # Indicate a significant increase or decrease (p≤0.05), respectively, by 
Student’s-t test.  





Fig 4. COX-1 contributes to cell viability in ovarian cancer cells. (A) Confirmation of COX-1 expression in COX-1 stable (SKCOX1) transfected 
cells. Whole cell lysates were prepared from each cell line and a western blot was carried out using a COX-1 specific antibody. β-Actin was used as a 
loading control; OVCAR-3 cells served as COX-1 positive cell line control. (B) Comparison of cell viability in COX-1 null SKpcDNA and positive SKCOX-1 
cells. Experiments were performed in triplicate and all data are shown as means ± SE. * Indicates a significant (p≤0.05) increase in SKCOX-1 cells compared 
to SKpcDNA cells when a Student’s-t test was made.  
 
Fig 5. ASA blocks EGFR-activated cell viability by blocking phosphorylation of Erk and Akt in COX-1 expressing cells. Effects of aspirin on 
EGFR-activated cell viability in SKpcDNA (A) and SKCOX-1 cells (B). Cells were treated for 48 hours with aspirin (1 mmol/L) in the absence or presence 
of EGF (10 ng/ml). The cell viability assay was performed by using MTT, and values were normalized to untreated controls. Experiments were performed 
in triplicate and all data are shown as means ± SE. *, # Indicate a significant increase or decrease (p≤0.05), respectively, by Student’s-t test. The inhibitory 
effect of aspirin on EGFR, Erk and Akt activation in SKpcDNA (C) and SKCOX-1 cells (D) by western blot analysis. Cells were pretreated with aspirin (1 
mmol/L) for 24 hours followed by the addition of EGF (10 ng/ml) for 0-120 minutes. pEGFR, pErk and pAkt indicate phosphorylated EGFR, Erk and Akt, 
respectively. β-Actin was used as a loading control. 





One of the primary findings in this study is that 
aspirin inhibits EGFR-activated cell viability in a 
COX-1 dependent manner by blocking phosphoryla-
tion of Akt and Erk in COX-1 positive ovarian cancer 
cells. Reportedly, some authors found that ovarian 
cancer cells express higher levels of COX-1 than 
COX-2 [18, 19] while others report a similar expres-
sion of COX-1 (59.9%) and COX-2 (60.3%) in epithelial 
ovarian cancer cells [31]. In our studies, OVCAR-3 
cells expressed COX-1 while the other three cell lines 
(SKOV-3, A2780 and TOV-21G) did not. Aspirin in-
hibited cell viability in COX-1 expressing OVCAR-3 
cells (figure 1A) as observed by others using COX-1 
expressing ovarian cancer cells [18-20, 22]. Since the 
relationship between aspirin use and the risk ovarian 
cancer is controversial [9, 12-17], these findings sug-
gest that the status of COX-1 expression in tumor 
subtypes needs to be considered in order to judge 
whether or not aspirin will be effective. 
As malignant ovarian cancer cells express higher 
levels of EGFR when compared to nonmalignant type 
cells [24, 25], targeting EGFR could be a useful ap-
proach to treating ovarian cancer. Because aspirin 
inhibited EGF-stimulated cell viability in COX-1 ex-
pressing OVCAR-3 cells (figure 2A), our findings 
suggest an interaction between an EGFR-activated 
signaling pathway and COX-1. We found that aspirin 
blocked EGFR downstream Erk and Akt activation 
(figure 2) which is consistent in part with other re-
ports about the inhibitory effect of aspirin on tumor 
cell growth by inhibiting Erk [22] and by 
down-regulating Akt activity [31]. In addition, aspirin 
did not attenuate EGF-stimulated cell proliferation in 
COX-1 knockdown cells (figure 3), indicating the in-
volvement of COX-1. Overexpression of COX-1 ac-
celerated cell viability (figure 4) suggesting it too may 
be a potential target for the prevention and treatment 
of ovarian cancers expressing this enzyme [20]. Fur-
thermore, transfecting a COX-1 null ovarian cancer 
cell line with COX-1 increased the level of cell viabil-
ity in response to EGF (figure 5A and 5B). 
Although further studies are required to clarify 
the relationship between EGFR signaling pathways 
and COX-1 in ovarian cancer, here we show that as-
pirin blocked EGF-stimulated Akt and Erk activation 
in COX-1 stable transfected cells (figure 5C and 5D). 
This fact indicates a COX-1-dependent effect of aspi-
rin rather than a direct effect of aspirin on 
EGFR-activated signaling. As aspirin potentiated the 
effects of a histone deacetylase inhibitor in COX-1 
positive ovarian cancer cells [23], it may also potenti-
ate the efficacy of EGFR inhibitors. Although soraf-
enib, a tyrosine kinase inhibitor, has become the 
first-line therapy for advanced hepatocellular carci-
noma, it also promotes the invasiveness and metasta-
sis of hepatocellular carcinoma [32]. Interestingly, 
aspirin minimizes the pro-metastasis effect of soraf-
enib in hepatocellular carcinoma, resulting in im-
proved survival in a mouse model [33]. Therefore, 
while aspirin cannot be the primary medication to 
treat cancer, when COX-1 is involved, aspirin could be 
used as a supportive medication to enhance EGFR 
based therapy. 
In conclusion, aspirin inhibits EGFR-activated 
cell viability by blocking Akt and Erk activation in a 
COX-1 dependent manner, probably leading to po-
tentiate the efficacy of chemotherapy treatments par-
ticularly in COX-1 positive ovarian cancer subsets. 
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